Cargando…

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)

SIMPLE SUMMARY: SBI-46, an antiandrogen-equipped histone deacetylase inhibitor, is the lead compound developed for targeting castration-resistant prostate cancer (CRPC). We determined the anticancer effect of SBI-46 on in vitro and in vivo models of CRPC. In our results, SBI-46 downregulates AR and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandrasekaran, Balaji, Tapadar, Subhasish, Wu, Bocheng, Saran, Uttara, Tyagi, Ashish, Johnston, Alexis, Gaul, David A., Oyelere, Adegboyega K., Damodaran, Chendil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046692/ https://www.ncbi.nlm.nih.gov/pubmed/36980655 http://dx.doi.org/10.3390/cancers15061769

Ejemplares similares

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
por: Makino, Tomoyuki, et al.
Publicado: (2021)

RETRACTED ARTICLE: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2021)

Retraction Note: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
por: Zhang, Boya, et al.
Publicado: (2023)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

$^{43}$Ar and $^{44}$Ar
por: Hudis, J, et al.
Publicado: (1970)

$^{43}Ar$ and $^{44}Ar$
por: Hudis, J, et al.
Publicado: (1970)

To Be(Ar) Or Not to Be(Ar) – Jones Dilemma?
por: Andrews, Nicholas A., et al.
Publicado: (2022)

KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC
por: Wang, Hung-Jung, et al.
Publicado: (2018)

Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents
por: Tapadar, Subhasish, et al.
Publicado: (2020)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

Emerging proteins involved in castration-resistant prostate cancer via the AR-dependent and AR-independent pathways (Review)
por: Feng, Kangle, et al.
Publicado: (2023)

Ár njöt'i ar hai = El color de la tierra
Publicado: (2014)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
por: Labaf, Maryam, et al.
Publicado: (2022)

The mass of $^{32}Ar$ and $^{33}Ar$ for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

Masses of 32Ar and 33Ar for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

Corrigendum: A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth
por: Saran, Uttara, et al.
Publicado: (2023)

A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth
por: Saran, Uttara, et al.
Publicado: (2023)

Determination of $^{44}Ar$(n,$\gamma$)$^{45}$Ar, and $^{46}$Ar(n,$\gamma$)$^{47}$Ar reaction rates by (d,p) transfer reactions
por: Sorlin, O, et al.
Publicado: (2002)

ARS Leptogenesis
por: Drewes, M., et al.
Publicado: (2017)

Ars melancholiae
por: Weiss, Silvius Leopold, 1686-1750
Publicado: (1994)

Ars Obstetrica
por: Armytage, V. B. Green
Publicado: (1930)

Ars Gynæcologica
por: Green-Armytage, V. B.
Publicado: (1930)

Ars Obstetrica
por: Umachigi, V. S.
Publicado: (1930)

Ars Longa
Publicado: (1893)

Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism
por: Shah, Supriya, et al.
Publicado: (2016)

Boutique neutrons advance (40)Ar/(39)Ar geochronology
por: Rutte, Daniel, et al.
Publicado: (2019)

Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52
por: Joshi, Jugal Bharat, et al.
Publicado: (2017)

Citrus Flavone Tangeretin Inhibits CRPC Cell Proliferation by Regulating Cx26, AKT, and AR Signaling
por: Zhang, Ningfang, et al.
Publicado: (2022)

ASR488, a novel small molecule, activates an mRNA binding protein, CPEB1, and inhibits the growth of bladder cancer
por: Tyagi, Ashish, et al.
Publicado: (2020)

A Comprehensive Transcriptomic Analysis of Arsenic-Induced Bladder Carcinogenesis
por: Shukla, Vaibhav, et al.
Publicado: (2022)

Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
por: Claessens, Frank, et al.
Publicado: (2008)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)

GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation
por: Su, Bing, et al.
Publicado: (2019)

Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013)

Crosstalk between KIF15 and AR in castrate-resistant prostate cancers
por: Yang, Hanny, et al.
Publicado: (2022)

Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models
por: Thomas, Elizabeth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gm5334kkgsq9o5f7ettlgt69dh